News

AI revolutionizes ophthalmology with enhanced diagnostics, personalized treatments, and improved surgical precision, offering better patient outcomes and efficient clinical trials.

This approach helps distinguish diseases associated with macular atrophy.

The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe.

Atrophy Advisor aids physicians in personalizing treatment for geographic atrophy in age-related macular degeneration, enhancing patient care and outcomes.

Dr. Quan Dong Nguyen presents interim data from the phase 3 DRAGON study on a potential first therapy for adolescent Stargardt disease.

Explore the evolving challenges and insights in long-term follow-up for pediatric gene therapy, focusing on data integrity, ethical considerations, and patient retention.

Lock in patient adherence with discussion of study results.

Results showed reduction in geographic atrophy progression and improved visual acuity.

Combining imaging and patient symptoms improves assessment of disease progression.

Xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across multiple retinal diseases and conditions.

New research highlights iron dysregulation's role in dry AMD, suggesting transferrin as a promising treatment to slow disease progression.

K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.

Gene therapy revolutionizes retinal disease treatment, offering long-lasting solutions and reducing the need for frequent injections in patients with nAMD.

Geographic atrophy management evolves with proactive imaging, personalized therapies, and real-world insights, enhancing patient care and treatment outcomes.

nAMD treatment options may offer positive outcomes to patients by reducing fluid fluctuations associated with poorer outcomes.

Guest lecturer explores the emerging frontiers in ROP therapy and the evolving ethical, clinical, and technological considerations.

Ophthalmology advances with AI diagnostics and pediatric trauma insights, merging technology and compassion to enhance patient care and outcomes.

Choroidal dysfunction plays a crucial role in retinal diseases, highlighting its potential as a therapeutic target and the need for innovative treatments.

Dr. Sharon Fekrat presented a retrospective analysis assessing how antiplatelet and anticoagulant therapy relates to hemorrhage characteristics and outcomes.

Sharon Fekrat discusses the complexities of antithrombotic use in wet AMD, highlighting the need for individualized treatment and future guideline development.

Remote monitoring of age-related macular degeneration enhances patient care, reduces treatment burden, and leverages AI for personalized management.

Prof Dr Rajvardhan Azad explains how unified guidelines, AI-driven tools, and cross-disciplinary collaboration could transform outcomes for premature infants.

Priyanka Sanghi, BSc, MSc, MBBS, highlights how fundus autofluorescence and optical coherence tomography may help uncover long-term retinal footprints invisible to standard examination.

Innovative multimodal deep learning models enhance non-invasive chronic kidney disease screening by integrating retinal images and urine dipstick data for improved accuracy.

Dr. Melissa Yuan discusses the impact of weight and postmenstrual age on foveal maturation in preterm infants, highlighting critical insights for neonatal care.

The Portal extension trial reveals that the Port Delivery System significantly improves vision in AMD patients, showcasing long-term efficacy and durability.

New treatments show promise in preventing fibrosis in neovascular AMD, addressing a critical need for improved visual outcomes in patients.